Chilco River Holdings Enters Premium Alcohol Beverage Sector, Targets Strategic Acquisitions to Accelerate Growth
Chatsworth, California--(Newsfile Corp. - May 29, 2025) - Chilco River Holdings, Inc. (OTC Pink: CRVH) ('Chilco' or the 'Company'), a rising force in brand acceleration, is thrilled to announce a transformative leap into the booming premium alcoholic beverage industry. This bold pivot marks the beginning of an ambitious growth strategy centered on acquiring standout brands and building a powerhouse portfolio in one of the most dynamic consumer markets.
The company is currently engaged in advanced negotiations with multiple acquisition targets including innovative upstarts and established premium labels. Chilco is positioning itself at the forefront of a surging industry driven by demand for craft spirits, ready-to-drink cocktails (RTDs), and luxury lifestyle beverages.
'The premium beverage space is exploding with opportunity,' stated, Chief Executive Officer, William Lovett. 'Our entry into this market is a game-changer, and we're already in deep discussions with brands that we believe can supercharge our trajectory and deliver lasting value to our shareholders.'
As part of this strategic realignment, the Company has formally canceled prior agreements with Leuffer Desarrollos SA de CV, American Hemp Brands, Inc., and L Myers Associates. These transactions were never consummated and no longer reflect the Company's core business objectives. This provides a fresh start and allows Chilco to dedicate full resources and strategic efforts toward the premium alcohol sector.
'This marks a clean slate and a bold new direction for Chilco,' continued Lovett. 'The premium beverage space is full of energy and opportunity, and we are excited to dive in. With the right strategy and execution, we believe we can build something truly impactful for our shareholders.'
In parallel with its renewed business direction, Chilco is proud to announce it has achieved Pink Current Information status with OTC Markets. This milestone not only underscores the Company's commitment to transparency but also unlocks powerful new levers for growth, including M&A activity, capital raising, and the onboarding of top-tier leadership.
With a clear vision and renewed focus, Chilco River Holdings is moving forward with determination and purpose. The Company is committed to transparency, disciplined execution, and consistent communication with shareholders. As it enters the premium alcohol space, Chilco is well-positioned to seize new opportunities and build lasting value in one of today's most dynamic markets.
About Chilco River Holdings, Inc.
Chilco River Holdings is a U.S.-based brand accelerator focused on identifying and acquiring premium consumer products with high-growth potential. The Company is currently targeting acquisitions in the premium alcohol beverage sector, including spirits, and ready-to-drink brands.
For more information, please contact:
Investor Relations
Chilco River Holdings, Inc.
Email: [email protected]
Website: www.chilcoriver.com
Forward-Looking Statements:
This press release contains forward-looking statements, including statements regarding the Company's strategic direction, acquisition plans, and anticipated growth. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially due to factors such as market conditions, due diligence outcomes, and regulatory approvals. Chilco River Holdings undertakes no obligation to update these statements, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253741
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
41 minutes ago
- Business Wire
Lazard Reports May 2025 Assets Under Management
NEW YORK--(BUSINESS WIRE)--Lazard, Inc. (NYSE: LAZ) reported today that its preliminary assets under management ('AUM') as of May 31, 2025 totaled approximately $235.3 billion. The month's AUM included market appreciation of $7.4 billion, net outflows of $3.7 billion, and FX appreciation of $0.2 billion. Outflows included $4.3 billion from a single sub-advised relationship. (1) Preliminary – subject to adjustment Expand About Lazard Founded in 1848, Lazard is one of the world's preeminent financial advisory and asset management firms, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. For more information, please visit Cautionary Note Regarding Forward-Looking Statements: This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by the use of forward-looking terminology such as 'may,' 'might,' 'will,' 'should,' 'could,' 'would,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'target,' 'goal,' 'pipeline,' or 'continue,' and the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies, business plans and initiatives and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. These factors include, but are not limited to, those discussed in our Annual Report on Form 10-K under Item 1A 'Risk Factors,' and also discussed from time to time in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including the following: Adverse general economic conditions or adverse conditions in global or regional financial markets; Changes in international trade policies and practices including the implementation of tariffs, proposed further tariffs, and responses from other jurisdictions, and the economic impacts, volatility and uncertainty resulting therefrom; A decline in our revenues, for example due to a decline in overall mergers and acquisitions (M&A) activity, our share of the M&A market or our assets under management (AUM); Losses caused by financial or other problems experienced by third parties; Losses due to unidentified or unanticipated risks; A lack of liquidity, i.e., ready access to funds, for use in our businesses; Competitive pressure on our businesses and on our ability to retain and attract employees at current compensation levels and; Changes in relevant tax laws, regulations or treaties or an adverse interpretation of those items. These risks and uncertainties are not exhaustive. Our SEC reports describe additional factors that could adversely affect our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for our management to predict all risks and uncertainties, nor can management assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. As a result, there can be no assurance that the forward-looking statements included in this release will prove to be accurate or correct. Although we believe the statements reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, achievements or events. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this release to conform our prior statements to actual results or revised expectations and we do not intend to do so. Lazard, Inc. is committed to providing timely and accurate information to the investing public, consistent with our legal and regulatory obligations. To that end, Lazard and its operating companies use their websites, and other social media sites to convey information about their businesses, including the anticipated release of quarterly financial results, quarterly financial, statistical and business-related information, and the posting of updates of assets under management in various mutual funds, hedge funds and other investment products managed by Lazard Asset Management LLC and Lazard Frères Gestion SAS. Investors can link to Lazard and its operating company websites through
Yahoo
an hour ago
- Yahoo
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
- The U.S. Food and Drug Administration (FDA) identified deficiencies at a third-party manufacturing vendor - FDA to provide final decision by PDUFA action date of June 28, 2025 LOS ALTOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY or the 'Company'), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced an update on its New Drug Application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The FDA communicated to the Company that it had identified deficiencies in cGMP compliance at a third-party manufacturing vendor (one of its CDMO's third-party subcontractors and not its Drug Substance vendor) following an FDA inspection. The FDA indicated that, given the identified deficiencies, any label discussions between the FDA and the Company are precluded. The Company has responded to all FDA information requests and expects a final decision from the FDA by the PDUFA action date of June 28, 2025. 'We are discussing with our partners to help resolve FDA's concerns and remain confident in the promise of OLC based on the extensive clinical and preclinical data we've generated,' said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. 'We believe OLC is a promising new treatment option and we are eager to bring it as quickly as we can to patients with CKD on dialysis who are living with hyperphosphatemia.' About Oxylanthanum Carbonate (OLC)OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden. Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. The NDA submission package is based on data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, and the chemistry, manufacturing and controls (CMC) data. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035. About HyperphosphatemiaHyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.2 Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream. About Unicycive TherapeuticsUnicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive's second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit and follow us on LinkedIn and X. Forward-looking statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Unicycive's Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.1 Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004 Aug;15(8):2208-18. doi: 10.1097/ PMID: 15284307.2 Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145. Epub 2023 Jun 29. PMID: 37229723; PMCID: PMC10371371. Investor Contact:Kevin GardnerLifeSci Advisorskgardner@ Contact:Rachel Visi Real Chemistryredery@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Rokmaster Closes $450,000 Financing
VANCOUVER, BC, June 10, 2025 /CNW/ - Rokmaster Resources Corp. (TSXV: RKR) (OTCQB: RKMSF) (FSE: 1RR1) ("Rokmaster" or "the Company") is pleased to announce that it has closed the non-brokered financing (the "Financing") announced on April 4, 2025 involving the issuance of flow-through shares (the "FT Shares") and non-flow-through units (the "NFT Units") for total gross proceeds of $450,000. Pursuant to the Financing, the Company issued a total of 6,250,000 FT Shares at $0.04 per FT Share, for gross proceeds of $250,000, and 10,000,000 NFT Units at $0.02 per NFT Unit, for gross proceeds of $200,000. Each NFT Unit will consist of one common share plus one-half (1/2) non-transferable share purchase warrant (a "Warrant"). Each whole Warrant is exercisable to purchase one additional common share of the Company (the "Warrant Share") at $0.05 for a period of two years expiring on June 9, 2027. The Warrants are subject to an accelerated expiry date, which comes into effect when the trading price on the TSX Venture Exchange of the Company's common shares closes at or above $0.10 per share for a period of 10 consecutive trading days commencing on October 10, 2025. In such event, the Company may, at its option, accelerate the expiry date of the Warrants by issuing a press release (the "Notice") to the Warrant holders and in such case, the expiry date of the Warrants will be 30 days from the date of the Notice. The securities issued pursuant to the Financing are subject to a four-months and one day hold period expiring October 10, 2025 and were not offered or registered in the United States. The gross proceeds raised from the sale of the FT Shares will be used by the Company for exploration financing that will qualify as "Canadian Exploration Expenses", as that term is defined in the Income Tax Act (Canada) only. The net proceeds raised from the sale of the NFT Units will be used by the Company on non-flow-through eligible exploration project expenses, share issuance costs related to the Financing, as well as for general working capital purposes which do not include payments to non-arm's length parties, investor relations activities and for specific expenses representing 10% or more of the gross proceeds from the issuance of NFT Units. Certain insiders of the Company acquired a total of $45,000 of the NFT Units and as such a portion of the Financing is considered a related party transaction as defined in the Exchange's Policy 5.9 and Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying upon the exemption from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the shares subscribed for, nor the consideration paid for the shares, exceeds 25% of the Company's market capitalization. On Behalf of the Board of Directors of Rokmaster Resources Corp. John Mirko,President & Chief Executive Officer. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term in defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS: This news release may contain forward-looking information within the meaning of applicable securities laws ("forward-looking statements"). Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," 'projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur. These forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements, including, without limitation; risks related to fluctuations in metal prices; uncertainties related to raising sufficient financing to fund the planned work in a timely manner and on acceptable terms; changes in planned work resulting from weather, logistical, technical or other factors; the possibility that results of work will not fulfill expectations and realize the perceived potential of the Company's properties; risk of accidents, equipment breakdowns and labour disputes or other unanticipated difficulties or interruptions; the possibility of cost overruns or unanticipated expenses in the work program; the risk of environmental contamination or damage resulting from Rokmaster's operations and other risks and uncertainties. Any forward-looking statement speaks only as of the date it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future vents or results or otherwise. SOURCE Rokmaster Resources Corp. View original content to download multimedia:
